Moderna, Inc. (MRNA) News

Moderna, Inc. (MRNA): $118.07

-4.08 (-3.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MRNA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 385

in industry

Filter MRNA News Items

MRNA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MRNA News Highlights

  • MRNA's 30 day story count now stands at 25.
  • Over the past 27 days, MRNA's stories per day has been in a clear uptrend, growing by about 0.73 per 3 days.
  • BA, DRUG and PFE are the most mentioned tickers in articles about MRNA.

Latest MRNA News From Around the Web

Below are the latest news stories about MODERNA INC that investors may wish to consider to help them evaluate MRNA as an investment opportunity.

Why Moderna Was a Sickly Stock Today

A shuffle at the top of the executive ranks, combined with the continued decline of the coronavirus, rattles some investors.

Yahoo | September 29, 2022

UPDATE 1-Around 3.2 mln Americans received updated COVID boosters last week -CDC

Around 3.2 million people in the United States received updated COVID-19 booster shots over the past week, the Centers for Disease Control and Prevention said on Thursday. The 7.6 million figure represents only 3.5% of the 215.5 million people in the United States aged 12 or older who are eligible to receive the shots because they have completed their primary vaccination series. The shots are being administered at a slower pace than last year, when the United States initially authorized COVID boosters just for older and immunocompromised people.

Yahoo | September 29, 2022

EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster

The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222, designed to target the Omicron BA.4 and BA.5 subvariants.

Yahoo | September 29, 2022

Pfizer (PFE), BNTX Seek EU Nod for Omicron Booster in Kids

Pfizer (PFE) and BioNTech seek to expand the EU label of their Omicron BA.4/BA.5-adapting bivalent COVID vaccine for children. It is already authorized for use in adolescents and adults.

Yahoo | September 29, 2022

These 2 Growth Stocks Have Fallen Out of Grace. Are They Buys?

In the past two years, biotech companies Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) rose to fame thanks to their successful attempts to develop vaccines for COVID-19 and help us end the outbreak. The pandemic isn't over yet, but Moderna and Novavax have given up substantial chunks of their value in the past year. Where does that leave Moderna and Novavax?

Yahoo | September 29, 2022

Moderna Creates New Executive Committee Role Ahead of New Product Launches

Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the Company has expanded the Executive Committee to prepare for multiple upcoming new product launches. Effective January 1, 2023, Juan Andres will step into a new role as President, Strategic Partnerships and Enterprise Expansion, and will focus on building out the organization to support the growing pipeline.

Yahoo | September 29, 2022

7 Growth Stocks to Buy Before the Bull Market Returns

These Growth Stocks to Buy Before the Bull Market Returns are trading at historical lows and offer massive upside potential

Muslim Farooque on InvestorPlace | September 28, 2022

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

Moderna (MRNA) closed at $122.15 in the latest trading session, marking a -0.07% move from the prior day.

Yahoo | September 28, 2022

Why Moderna Stock Lagged the Market Today

This was the case with high-profile biotech Moderna (NASDAQ: MRNA) on Wednesday. Moderna's positive news came from across the Atlantic Ocean, where the European Medicines Agency (EMA) accepted a conditional marketing authorization (CMA) application for the company's bivalent coronavirus booster vaccine. Moderna didn't hesitate to point out that the new booster has already been given the green light by the U.S. Food and Drug Administration (FDA) and a host of other jurisdictions, including Australia, Taiwan, and the U.K.

Yahoo | September 28, 2022

COVID-19: Young, healthy people may not need bivalent boosters, vaccine expert says

Data is still scarce on latest COVID-19 boosters

Yahoo | September 28, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6575 seconds.